Stock fact sheet · data as of
Baxter International Inc. (BAX): fair value, margin of safety and Wheel Score
Healthcare · Medical - Instruments & Supplies · United States · Speculative / Distressed
Is BAX undervalued?
At 25.76 (close of 16 Oct 2026), BAX trades within a few percent of the GLS average fair value of 24.77 (4.0% above fair value). 2 models produced a value and they split 1 above the price to 1 below. A stock priced at fair value earns about half of the Wheel Score's Value points; the rest of the score comes from health, moat, premium and stability.
The average is built from just 2 models (10 Cap, DDM) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files BAX under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for BAX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 48.95 | +90% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | 0.5886 | -98% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -13.70 | -153% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 23.60 | -8% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Baxter International Inc. scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 2.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -5.9%, ROE -15.6%, ROA -4.8% - with debt at 1.63 times equity and a free-cash-flow yield of 5.1%.
The dividend yield is 0.16% with a payout ratio of -18% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from Medical Products And Therapies 72%, Healthcare Systems and Technologies 28% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 5/10 and Congressional trading 10/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | -5.9% |
|---|---|---|---|
| GLS Moat | 2.0 / 10 | ROE | -15.6% |
| Debt / equity | 1.63 | ROA | -4.8% |
| Free-cash-flow yield | 5.1% | Payout ratio | -18% |
| Institutions | 10 / 10 | Insiders · Congress | 5 · 10 / 10 |
Wheel Score 45: Weak
With a Wheel Score of 45 Baxter International Inc. sits in the Weak band, capped at 45 because the engine files it as Speculative / Distressed. The parts - Value 11/25, Health 9/20, Moat 3/15, Premium 20/20, Stability 20/20 - show where: Moat (3/15) scores lowest.
Implied volatility is 54% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. The option chain is deep: 86,277 contracts of open interest across all expiries, which means tight fills at most strikes.
Volume runs at 4.5M shares a day on a market cap of $13.3B, with a beta of 0.65 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 20 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 11 / 25 | -4% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 3 / 15 | moat 2.0/10 | |
| Premium | 20 / 20 | implied volatility 54% | |
| Stability | 20 / 20 | 4.5M shares/day, $13.3B cap, beta 0.65 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
Baxter International Inc. reports earnings on 29 Oct 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Instruments & Supplies
The 12 companies below are the closest to Baxter International Inc. by market cap within the Medical - Instruments & Supplies industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| SOLV Solventum Corporation | 87.26 | 100.23 | +13% | 79Good | $14.9B |
| RGEN Repligen Corporation | 178.20 | 25.50 | -599% | 58Fair | $11.3B |
| COO The Cooper Companies, Inc. | 57.40 | 51.06 | -12% | 65Good | $10.9B |
| AVTR Avantor, Inc. | 16.09 | 17.57 | +8% | 45Weak | $10.9B |
| ATR AptarGroup, Inc. | 124.26 | 102.12 | -22% | 60Fair | $7.9B |
| WST West Pharmaceutical Services, Inc. | 374.65 | 104.99 | -257% | 65Good | $26.4B |
| BLCO Bausch + Lomb Corporation | 16.66 | 10.95 | -52% | 45Weak | $6.0B |
| MDLN Medline Inc. | 36.57 | 37.97 | +4% | 80Prime | $32.1B |
| RMD ResMed Inc. | 235.29 | 307.44 | +23% | 87Prime | $33.1B |
| MMSI Merit Medical Systems, Inc. | 89.57 | 65.92 | -36% | 59Fair | $5.3B |
| STVN Stevanato Group S.p.A. | 19.31 | 10.82 | -79% | 58Fair | $5.3B |
| TFX Teleflex Incorporated | 123.29 | 85.49 | -44% | 45Weak | $5.2B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about BAX
Is BAX undervalued right now?
Not meaningfully: at 25.76 the stock trades within a few percent of the GLS average fair value of 24.77 (4.0% above fair value, data as of 16 Oct 2026).
What is the Wheel Score of BAX and what does it mean?
BAX scores 45 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for BAX?
24.77 per share as of 16 Oct 2026 - the simple average of the 2 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Baxter International Inc. report earnings next?
The next earnings report is due on 29 Oct 2026 (before the open), 13 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does BAX have listed options, and how liquid are they?
Yes. The nightly snapshot found 580 listed contracts with 86,277 open interest across all expiries and implied volatility of 54% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.